Replicel Announces Update on Filing of Interim Financial Statements and MD&A Due to COVID‐19 Related Delays

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学
Published on: September 28, 2020

VANCOUVER, BC – September 28, 2020 – Replicel Life Sciences Inc. (the “Company” or “Replicel”) announces that further to its News Release of August 28, 2020, there have been no material business developments since August 28, 2020; however, the Company has issued a news release subsequent to August 28, 2020, a copy of which is available on SEDAR at www.sedar.com. The Company estimates that its interim financial statements and management’s discussion and analysis for the six‐month period ended June 30, 2020 (the “Interim Documents”) will be available for filing at its earliest opportunity, which is expected to occur on or before October 15, 2020, which is in compliance with the relief provided by British Columbia Instrument 51‐517, Alberta Securities Commission Blanket Order 51‐519 and Ontario Instrument 51‐505.

For more information, please contact:

Telephone: 604‐248‐8693 / [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward‐looking statements and information that involve various risks and uncertainties regarding future events, including, but not limited to, statements regarding the estimated date of filing of the Interim Documents.

These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward‐ looking statements, including: risks that the COVID‐19 pandemic and associated consequences will result in additional delays in the preparation of the Company’s Interim Documents and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward‐looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward‐looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward‐looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward‐looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20‐F for the fiscal year ended December 31, 2019 and other periodic reports filed from time‐to‐time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Biotechnology Genomics Medical Device